Corvus Pharmaceuticals, Inc. (CRVS) Misses Q4 EPS by 6c

Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) reported Q4 EPS of ($0.18), $0.06 worse than the analyst estimate of ($0.12).

For earnings history and earnings-related data on Corvus Pharmaceuticals, Inc. (CRVS) click here.

You May Also Be Interested In

• ​Trump said he was unaware of his earnings from crypto
• Midera Food Processing and Centrus Energy to join S&P SmallCap 600
• Trifecta Gold closes $1.66M private placement for Yukon exploration